Cancers · 2021 · 18 citations · 36 references
MedicineOncologyPharmacologyChemotherapyDna RepairMolecular OncologyCancer Cell SignalingCell Cycle PharmacologyCell-cycle DysregulationCyclin-dependent KinasesCytotoxic ChemotherapyEndometrial CancerBcl-2 InhibitionBcl-2 Protein ExpressionCdk InhibitorsCell Cycle InhibitionCell Cycle InhibitorsCell Cycle-targeted TherapeuticsCyclin-dependent Kinase InhibitorsPrimary Cells
Endometrial cancer (EC) is the sixth most prevalent female cancer globally and although high rates of success are achieved when diagnosed at an early stage, the 5-year survival rate for cancers diagnosed at Stages II-IV is below 50%. Improving patient outcomes will necessitate the introduction of novel therapies to the clinic. Pan-cyclin-dependent kinase inhibitors (CDKis) have been explored as therapies for a range of cancers due to their ability to simultaneously target multiple key cellular processes, such as cell cycle progression, transcription, and DNA repair. Few studies, however, have reported on their potential for the treatment of EC. Herein, we examined the effects of the pan-CDKi dinaciclib in primary cells isolated directly from tumors and EC cell lines. Dinaciclib was shown to elicit a bimodal action in EC cell lines, disrupting both cell cycle progression and phosphorylation of the RNA polymerase carboxy terminal domain, with a concomitant reduction in Bcl-2 expression. Furthermore, the therapeutic potential of combining dinaciclib and cisplatin was explored, with the drugs demonstrating synergy at specific doses in Type I and Type II EC cell lines. Together, these results highlight the potential of dinaciclib for use as an effective EC therapy.
36
CellProfiler 3.0: Next-generation image processing for biology
Claire McQuin, Allen Goodman, Vasiliy S. Chernyshev et al. · PLoS Biology · 2018 · 2.1K citations · Full text
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry, Timothy J. Guzi, Nicole R. Davis et al. · Molecular Cancer Therapeutics · 2010 · 561 citations · Full text
Medicine, Oncology, Pharmacology +17
Frédéric Amant, Mansoor Raza Mirza, Martin Koskas et al. · International Journal of Gynecology & Obstetrics · 2018 · 352 citations · Full text
Medicine, Gynecology, Oncology +17